Explore the future of the global antibacterial vaccine market, anticipating growth from $22B to $40B by 2030, unveiling a lucrative landscape ripe for innovation.
Major regulatory advancements in the US and EU put Merck, GSK, and Sanofi at the forefront to grab a share of the lucrative antibacterial vaccine market.
Pfizer’s imminent launch of an adolescent vaccine hints at a strategic maneuver to fortify its vaccine portfolio.
Ready to delve deeper into the future of antibacterial vaccines?
Get a copy below.
Related Insights & Outlooks
Q3-2024 Top Pharma Earnings Results
•
November 18, 2024
From breakthrough therapies to strategic market maneuvers, here’s how the Top 15 Pharma Companies navigated the quarter’s challenges and opportunities.
Q2-2024 Top Pharma Earnings Results
•
August 14, 2024
The pharmaceutical industry showed impressive performance in Q2 2024, with a notable focus on innovation and expansion.
.avif)